Literature DB >> 30417494

Pyruvic acid/ethyl pyruvate inhibits melanogenesis in B16F10 melanoma cells through PI3K/AKT, GSK3β, and ROS-ERK signaling pathways.

Siqi Zhou1, Kazuichi Sakamoto1.   

Abstract

Melanin is the main product of human melanocytes and functions to protect skin from ultraviolet (UV) radiation while conferring color to skin and hair. Tyrosinase is the rate-limiting enzyme for melanin synthesis along with tyrosinase-related protein (TRP)-1 and TRP-2. Microphthalmia-associated transcription factor regulates tyrosinase gene expression and is in turn regulated by extracellular signal-regulated kinase (ERK), phosphoinositide 3-kinase (PI3K)/AKT, and glycogen synthase kinase (GSK)3β signaling pathways. Pyruvic acid (PA) is an energy source for ATP synthesis in the tricarboxylic acid cycle that also acts as a reactive oxygen species (ROS) scavenger. As UV irradiation induces melanin synthesis and ROS generation, we speculated that PA or ethyl pyruvate (EP), a stable form of pyruvate, regulates melanogenesis. B16F10 melanoma cells served as a melanin synthesis model. Treatment with PA or EP suppressed melanin synthesis while increasing intracellular ROS levels, which was accompanied by increased ERK phosphorylation in the case of EP treatment. PA and EP induced GSK3β phosphorylation and activated PI3K/AKT signaling, leading to decreased melanin synthesis. These results indicate that PA and EP inhibit melanogenesis via PI3K/AKT and GSK3β signaling and targeting the ERK and GSK3β pathways, respectively. Thus, PA and EP can potentially be used for treatment of hyperpigmentation disorders.
© 2018 Molecular Biology Society of Japan and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  AKT; ERK; GSK3β; ethyl pyruvate; melanogenesis; pyruvic acid

Mesh:

Substances:

Year:  2018        PMID: 30417494     DOI: 10.1111/gtc.12654

Source DB:  PubMed          Journal:  Genes Cells        ISSN: 1356-9597            Impact factor:   1.891


  6 in total

1.  Ethyl pyruvate inhibits glioblastoma cells migration and invasion through modulation of NF-κB and ERK-mediated EMT.

Authors:  Qing Huang; Yongming Fu; Shan Zhang; Youxiang Zhang; Simin Chen; Zuping Zhang
Journal:  PeerJ       Date:  2020-07-21       Impact factor: 2.984

2.  Disruption of Redox Homeostasis by Alterations in Nitric Oxide Synthase Activity and Tetrahydrobiopterin along with Melanoma Progression.

Authors:  Jaqueline Pereira Moura Soares; Diego Assis Gonçalves; Ricardo Xisto de Sousa; Margareth Gori Mouro; Elisa M S Higa; Letícia Paulino Sperandio; Carolina Moraes Vitoriano; Elisa Bachir Santa Rosa; Fernanda Oliveira Dos Santos; Gustavo Nery de Queiroz; Roberta Sessa Stilhano Yamaguchi; Gustavo Pereira; Marcelo Yudi Icimoto; Fabiana Henriques Machado de Melo
Journal:  Int J Mol Sci       Date:  2022-05-26       Impact factor: 6.208

Review 3.  Chloracne and Hyperpigmentation Caused by Exposure to Hazardous Aryl Hydrocarbon Receptor Ligands.

Authors:  Masutaka Furue; Gaku Tsuji
Journal:  Int J Environ Res Public Health       Date:  2019-12-03       Impact factor: 3.390

4.  Citric acid promoted melanin synthesis in B16F10 mouse melanoma cells, but inhibited it in human epidermal melanocytes and HMV-II melanoma cells via the GSK3β/β-catenin signaling pathway.

Authors:  Siqi Zhou; Kazuichi Sakamoto
Journal:  PLoS One       Date:  2020-12-17       Impact factor: 3.240

5.  Calycosin, a Common Dietary Isoflavonoid, Suppresses Melanogenesis through the Downregulation of PKA/CREB and p38 MAPK Signaling Pathways.

Authors:  Kun-Chang Wu; You-Cheng Hseu; Yu-Ching Shih; Govindan Sivakumar; Jyun-Ting Syu; Guan-Lin Chen; Meng-Tien Lu; Po-Chen Chu
Journal:  Int J Mol Sci       Date:  2022-01-25       Impact factor: 5.923

6.  The PI3K subunits, P110α and P110β are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer.

Authors:  Lei Zhang; Yidong Li; Qianchao Wang; Zhuo Chen; Xiaoyun Li; Zhuoxun Wu; Chaohua Hu; Dan Liao; Wei Zhang; Zhe-Sheng Chen
Journal:  Mol Cancer       Date:  2020-01-17       Impact factor: 27.401

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.